HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procter & Gamble Co.

www.pg.com

Latest From Procter & Gamble Co.

Henkel Acquires DevaCurl: Preface To Coty Professional Hair-Care Buy?

Analysts believe Henkel is a top contender to acquire Coty’s professional hair-care business, which ranks second in the world after L’Oreal’s, with Henkel’s a distant third. According to Kline’s Carrie Mellage, the DevaCurl deal shows the German firm’s enduring appetite for M&A following a series of similarly small, US-focused purchases in recent years that could be leading to something much larger.

Beauty Business Strategies

P&G Extends Secret Line With Essential Oils, Challenges 'Sweat' With Old Spice

P&G rolls out Secret with Essential Oils with aluminum zirconium tetrachlorohydrex glycine 15, retailing at more than twice price of other Secret antiperspirant/deodorant lineup items. Firm also adds "No Sweat" ad campaign for Old Spice deodorants.

Cosmetics Ad Campaigns

Coty Would Shrink By A Third With Professional, Brazil Biz Divestures; Analysts React

The world’s third-largest beauty company is changing direction following an acquisition tear in recent years, now exploring strategic options for its Professional hair care/salon and Brazilian businesses to reduce debt and sharpen its focus on Luxury and Consumer fragrance, makeup and skin care. The 21 October announcement has lifted Coty’s stock roughly 18%, though analyst takes are mixed.

Beauty Deals

Innovating Outside OTC Monograph Lines: Trending Acne Patches, Hand And Foot Antiperspirants

Industry and the FDA agree that the OTC drug monograph system is direly in need of reform, but innovating with noncompliant dosage forms and indications, without approved new drug applications, is a risk companies need to weigh seriously, says Arnall Golden Gregory partner Alan Minsk. The FDA offers perspective on its OTC monographs for acne and antiperspirant products.

United States Regulation
See All

Company Information

UsernamePublicRestriction

Register